Figure 2.
![Kaplan-Meier estimates of efficacy end points by MRD∗ response status at EOT in the overall intent-to-treat population. (A) PFS; (B) OS. Fisher’s exact test was performed to compare MRD status at EOCT and EOT. ∗MRD was categorized as uMRD (<1 CLL cell per 10 000 leukocytes; MRD value <0.0001 [10–4]) and MRD+ (≥10–4).](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/145/23/10.1182_blood.2024025525/2/blood_bld-2024-025525-gr2.jpeg?Expires=1752363149&Signature=GLgo-EOlVfcaI1VFOa2mtyTIZOuineg20y3nEq-8V1JqtqB2EUrFZGB46Y4eF~QvZzIyYsB1ggWftCuGeCJx6XRyj05Jst5FuFd8SYf9ZQ96LXxOSq5L5U55sMHcPw-DrONID93oZzsMthR55zmMbVSc722JB7c2Vg~Qou9T2v7aCvfOwYeHKo7jMlOvRBu3lBOXSTBQCIfdAaJ6e5oqMy94fSMuOrXP2tlBCzB6O1TBU21EGBHzqAZZGj61hcSOHOAr0x4kmnd72DMFKEQpqbU05-Q2UMLgi5Nx8yNaJ3Hx4gqGmOB3wpC7ofhZesGeDZ-FOP~rzc0Knl0DO7XJuw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
Kaplan-Meier estimates of efficacy end points by MRD∗ response status at EOT in the overall intent-to-treat population. (A) PFS; (B) OS. Fisher’s exact test was performed to compare MRD status at EOCT and EOT. ∗MRD was categorized as uMRD (<1 CLL cell per 10 000 leukocytes; MRD value <0.0001 [10–4]) and MRD+ (≥10–4).
